
Low Incidence of Immediate Adverse Events in Clinical Uses1-7
Dotarem® has been tested in more than studies - it has also withstood the test of real-world clinical uses.1
- 4.0% in clinical trials (N=2822)
- 0.7% considered serious
- <1% in postmarketing studies (N>150,000)
- 0.007% reported spontaneously worldwide
(>50 million doses)- 0.0023% incidence rate of serious adverse events